Release Date: November 26, 2025
Expiration Date: November 26, 2026
Activity Overview
This Community Practice Connection™ program provides an in-depth review of some highlights from the 2025 Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice. This unique and engaging multimedia activity is ideal for community-based clinicians and focuses on the practical aspects of using DLL3-targeted bispecific T-cell engager therapy to manage patients with small cell lung cancer (SCLC), helping clinicians to place recent clinical trial data into context. The program is designed for those who did not attend the live program and to help reinforce learnings for those who did.
Target Audience
This educational program is primarily directed toward community-based oncologists and other health care providers involved in the treatment of SCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the rationale and mechanism of actions for emerging DLL3-targeted agents, including bispecific antibodies, antibody drug conjugates, and chimeric antigen receptor T-cell therapies
- Evaluate the latest trial data on DLL3-targeting therapies in SCLC
- Implement care plans to monitor and mitigate common adverse effects of DLL3-targeted therapies using evidence-based management approaches
- Apply strategies to effectively coordinate care between the community cancer and academic centers
Jacob Sands, MD
Associate Chief, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor
Harvard Medical School
Boston, MA
Disclosures: Adviser, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Fosun, Genentech, Jazz Pharmaceuticals, Gilead, Merck, Novartis, Pfizer, Sanofi, Medtronic; Grant/Research Funding: Amgen, Harpoon, Novartis
Anne Chiang, MD, PhD
Associate Professor, Division of Thoracic Medical Oncology
Yale University School of Medicine
Associate Cancer Center Director, Clinical Initiatives
Yale Cancer Center
New Haven, CT
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Fosun, Genentech, Janssen, Jazz, Merck, Zai Lab; Grant/Research Funding: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Genentech, Zai Lab
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here